



CAR T-CELL THERAPY FOR SOLID TUMOURS



Dr. Kerstin Papenfuss, Cell and Gene Therapy Catapult

CHIMERIC THERAPEUTICS

- Established October 2015
- Special Purpose Vehicle for collaborative project:
 - **Cell and Gene Therapy Catapult (CGTC)**
 - **University of Birmingham**
 - **Cancer Research UK (CRUK)**
- Run as a virtual company
- Funded by Cancer Research UK and Catapult
- Comprehensive patent portfolio
- Track record: The Catapult team have previously successfully advanced a TCR-cell immunotherapy from preclinical studies into clinical trials which has since been acquired by Cell Medica. CRUK have significant experience in this space.




THERAPEUTIC APPROACH: CLEC14A-CAR-T



- **CLEC14A** is a **tumour endothelial marker (TEM)** preferentially expressed on the vasculature of a range of solid tumours in abnormal vasculature but not normal tissue
- CLEC14A-targeted CAR-T therapy acts as a novel **vascular disruptive agent (VDA)**
- POC has been obtained in **3 different in vivo models** demonstrating efficacy and safety


DEVELOPMENT PLAN 3rd GEN. CAR-T

- Preclinical program to be completed by Q1 2020
- CLEC14A CAR-T cell non-clinical safety programme agreed with the MHRA
- Finalisation of Clinical Trial Design and follow up scientific advice meeting with the MHRA
- Ongoing development of companion biomarker



SOLID TUMOURS - A BROAD COMMERCIAL OPPORTUNITY

- Solid tumours – significant **unmet need** with large commercial opportunity
- CLEC14A is upregulated in **multiple solid tumours** and presents unique broad application for solid tumour anti-cancer therapy
- **Novel approach:** CAR T acts on solid tumours through novel MOA
- **Versatility:** an attractive option for combination approaches, increasing therapeutic options for difficult to treat patients.



CHIMERIC THERAPEUTICS IS LOOKING FOR...

- Catapult is a non-for profit organization funded by the UK-government
- Aim is to bring the treatment closer to the patients
- Move through GMP transfer and into FIH trials
- Looking for
 - investment to fund the clinical trials
 - co-development partners with interest in in-licensing pre-clinical assets or collaborative models